市場調查報告書

β型干擾素藥的全球市場 - 各產品種類·各給藥途徑·各流通管道·各地區:市場規模·佔有率·未來展望·機會分析

Interferon Beta Drugs Market, by Product Type, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版商 Coherent Market Insights 商品編碼 968791
出版日期 內容資訊 英文 169 Pages
商品交期: 2-3個工作天內
價格
β型干擾素藥的全球市場 - 各產品種類·各給藥途徑·各流通管道·各地區:市場規模·佔有率·未來展望·機會分析 Interferon Beta Drugs Market, by Product Type, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
出版日期: 2020年10月19日內容資訊: 英文 169 Pages
簡介

現在世界各國多發性硬化症的人數持續增加,這是乾擾素β藥物的主要市場驅動力。

本報告提供全球干擾素β藥的市場相關分析,提供產品概要和背景情況,市場基本結構及促進·阻礙因素,整體市場規模預測 (以金額為準,過去4年·今後8年份),各產品種類·各給藥途徑·各流通管道·各地區的詳細趨勢,主要企業的簡介·業績·策略計劃等調查。

目錄

第1章 分析目的·前提條件

第2章 市場概要

  • 分析概要
    • 市場定義和範圍
  • 摘要整理
  • COM (Coherent Opportunity Map:市場機會藍圖)

第3章 市場力學·規定·趨勢分析

  • 市場動態
  • 促進因素
  • 阻礙因素
  • 影響分析
  • 市場機會
  • 事業聯盟·企業收購
  • 產品銷售
  • 開發平台分析
  • 醫療費償付方案
  • 法規方案

第4章 全球β型干擾素藥市場:COVID-19感染擴大的影響

  • COVID-19後的影響
  • COVID-19對軟體凝膠生產的影響
  • 供需趨勢分析
  • 對製造業的整體影響

第5章 全球β型干擾素藥市場:各產品種類

  • 簡介
    • 市場佔有率分析 (最新值·預測值)
    • 與前一年同期相比成長率 (YoY)的分析 (實際成果值·預測值)
    • 各市場區隔趨勢
  • β型干擾素-1A
    • 簡介
    • 市場規模與其預測,與前一年同期相比成長率 (YoY) (以金額為準)
  • β型干擾素-1B
  • β型干擾素-1A

第6章 全球β型干擾素藥市場:各給藥途徑

  • 簡介
  • 肌肉內注射 (IM)
  • 皮下注射
  • 靜脈內注射 (IV)

第7章 全球β型干擾素藥市場:各流通管道

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第8章 全球β型干擾素藥市場:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 南美
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他的南美各國
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他的歐洲各國
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 韓國
    • 東南亞國協
    • 其他的亞太地區各國
  • 中東
    • 波灣合作理事會 (GCC) 各國
    • 以色列
    • 其他的中東各國
  • 非洲
    • 北部非洲
    • 中部非洲
    • 非洲南部

第9章 競爭情形

  • 企業簡介
  • Biogen Idec
    • 企業概要
    • 產品/臨床實驗組合
    • 近幾年的主要趨勢
    • 財務實際成果
    • 市場策略
  • Merck KGaA
  • Novartis Pharmaceuticals Corporation
  • Bayer
目錄

Title:
Interferon Beta Drugs Market, by Product Type (Interferon Beta-1A, Interferon Beta-1B, and Peginterferon Beta-1A), by Route of Administration (Intramuscular, Subcutaneous, and Intravenous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Interferon beta drug is used to treat relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The drug does not completely cure the condition, but slows down progression of some of the disabling effects and decreases the number of relapses of the disease. Interferons are natural substances produced in the human body to help fight infections. Interferon beta drugs are categorized in Interferon Beta-1A, Interferon Beta-1B, and Peginterferon Beta-1A.

Market Dynamics

Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20-50 years. According to the Multiple Sclerosis Foundation, in 2017, this autoimmune condition affects 2.5 million people with an annual global incidence of around 7 cases per 100,000 people. The study also states that prevalence rates vary between ethnic and geographical latitudes, ranging from 50 to 120 people per 100,000. Moreover, according to the Multiple Sclerosis Foundation, 2015, an estimated 400,000 people live with the disease in U.S., and about 200 new cases are diagnosed every week. According to a survey by Healthline Media, 2015, multiple sclerosis ranks second after congestive heart failure with direct and indirect health care costs ranging from US$ 8,528 to US$ 54,244 per patient per year. Thus, increasing prevalence of multiple sclerosis is a major factor driving the growth of global interferon beta drugs market.

Key features of the study:

  • This report provides in-depth analysis of the global interferon beta drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020-2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global interferon beta drugs market based on the following parameters - company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are Biogen Idec., Merck KGaA, Novartis Pharmaceuticals Corporation, and Bayer
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global interferon beta drugs market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global interferon beta drugs market.

Detailed Segmentation:

  • Global Interferon Beta Drugs Market, By Product Type:
    • Interferon Beta-1A
    • Interferon Beta-1B
    • Peginterferon Beta-1A
  • Global Interferon Beta Drugs Market, By Route of Administration:
    • Intramuscular
    • Subcutaneous
    • Intravenous
  • Global Interferon Beta Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Interferon Beta Drugs Market, By Region:
    • North America
      • By Product Type:
      • Interferon Beta-1A
      • Interferon Beta-1B
      • Peginterferon Beta-1A
      • By Route of Administration:
      • Intramuscular
      • Subcutaneous
      • Intravenous
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.S.
      • Canada
    • Latin America
      • By Product Type:
      • Interferon Beta-1A
      • Interferon Beta-1B
      • Peginterferon Beta-1A
      • By Route of Administration:
      • Intramuscular
      • Subcutaneous
      • Intravenous
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Product Type:
      • Interferon Beta-1A
      • Interferon Beta-1B
      • Peginterferon Beta-1A
      • By Route of Administration:
      • Intramuscular
      • Subcutaneous
      • Intravenous
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Product Type:
      • Interferon Beta-1A
      • Interferon Beta-1B
      • Peginterferon Beta-1A
      • By Route of Administration:
      • Intramuscular
      • Subcutaneous
      • Intravenous
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Product Type:
      • Interferon Beta-1A
      • Interferon Beta-1B
      • Peginterferon Beta-1A
      • By Route of Administration:
      • Intramuscular
      • Subcutaneous
      • Intravenous
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Product Type:
      • Interferon Beta-1A
      • Interferon Beta-1B
      • Peginterferon Beta-1A
      • By Route of Administration:
      • Intramuscular
      • Subcutaneous
      • Intravenous
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles:
    • Biogen Idec
    • Merck KGaA
    • Novartis Pharmaceuticals Corporation
    • Bayer
  • "*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
  • Market Definition and Scope
  • Executive Summary
  • Market Snippet, By Product Type
  • Market Snippet, By Route of Administration
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Drivers
  • Restraints
  • Impact Analysis
  • Market Opportunities
  • Collaboration and acquisition
  • Product Launch
  • Pipeline Analysis
  • Reimbursement Scenario
  • Regulatory Scenario

4. Global Interferon Beta Drugs Market, Impact of COVID-19 Pandemic

  • Post COVID-19 Impact
  • COVID-19 Impact on Softgel Productions
  • Demand and Supply Analysis
  • Overall impact on manufacturing industry

5. Global Interferon Beta Drugs Market, By Product Type, 2016-2027 (US$ Mn)

  • Introduction
  • Market Share Analysis, 2020 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • Interferon Beta-1A
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • Interferon Beta-1B
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • Peginterferon Beta-1A
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)

6. Global Interferon Beta Drugs Market, By Route of Administration, 2016-2027 (US$ Mn)

  • Introduction
  • Market Share Analysis, 2020 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • Intramuscular
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • Subcutaneous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • Intravenous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)

7. Global Interferon Beta Drugs Market, By Distribution Channel, 2016-2027 (US$ Mn)

  • Introduction
  • Market Share Analysis, 2020 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)

8. Global Interferon Beta Drugs Market, By Region, 2016-2027 (US$ Mn)

  • Introduction
  • Market Share Analysis, By Country, 2020 and 2027 (%)
  • Y-o-Y Growth Analysis, For Countries, 2017-2027
  • North America
  • Introduction
  • Market Size and Forecast, By Product Type, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Application, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2016-2027 (US$ Mn)
    • U.S.
    • Canada
  • Latin America
  • Introduction
  • Market Size and Forecast, By Product Type, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Application, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2016-2027 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
  • Introduction
  • Market Size and Forecast, By Product Type, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Application, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2016-2027 (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
  • Introduction
  • Market Size and Forecast, By Product Type, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Application, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2016-2027 (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
  • Introduction
  • Market Size and Forecast, By Product Type, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Application, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2016-2027 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
  • Introduction
  • Market Size and Forecast, By Product Type, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Application, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2016-2027 (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

9. Competitive Landscape

  • Company Profiles
  • Biogen Idec
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Merck KGaA
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Novartis Pharmaceuticals Corporation
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Bayer
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Market Strategies

Browse 28 market data tables and 30 figures on " Global Interferon Beta Drugs Market - Global forecast to 2027".